Pfizer Drug Mycobutin Granted First Mycobacterosis Approval In Japan
This article was originally published in PharmAsia News
Pfizer announced July 16 that it obtained approval to manufacture and market its mycobacterosis drug Mycobutin (rifabutin). It's the first mycobacterosis drug in Japan. Rifabutin is also indicated to treat non-tuberculosis mycobacteri and multidrug-resistant tuberculosis. The drug is to treat the onset of MAC that is common among HIV carriers. Approved in 35 countries, Pfizer applied for approval with the Ministry of Health, Labor and Welfare last June. In Japan, the tuberculosis rate is 2.6 per 100,000 people, with around 26,000 people diagnosed each year. That's 1.5 time higher than in the UK and 5 times of the U.S. (Click here for more - Japanese language
You may also be interested in...
CV Defense, the second launch in the firm’s new immune-support line (without cannabidiol), is built around palmitoylethanolamide and other nutrients and botanicals to “optimize immune response.” CV Sciences touts the immunity range as complementary to its PlusCBD brand, which is in the process of rolling out dozens of new products in updated packaging.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
US, EU and Canadian authorities recently discussed their approaches to rolling reviews of CMC applications for coronavirus vaccines.